

NEWS RELEASE

Pharmaniaga on Strong Footing

KUALA LUMPUR, April 3, 2013 – As Malaysia’s largest listed integrated pharmaceutical group, Pharmaniaga Berhad is set to strengthen its business potential for the year ahead.

For its recently concluded financial year ended 31 December 2012, Pharmaniaga recorded a profit after tax of RM63 million, signifying a 19% jump compared with its 2011 financial year results. These sterling results were achieved on the back of an improved turnover of RM1.8 billion for the fiscal year compared with its 2011 financial year results.

YBhg Tan Sri Dato’ Seri Lodin Wok Kamaruddin, Chairman, Pharmaniaga Berhad commented after Pharmaniaga’s Annual General Meeting, “As a market leader in the pharmaceutical sector, we are pleased with the progress we have made particularly in improving operational efficiencies and strengthening our earnings potential.”

“Furthermore, with a proposed share split involving the subdivision of every one existing ordinary share of RM1 each into two ordinary shares of 50 sen each along with a proposed bonus issue, we are confident that Pharmaniaga’s liquidity will improve.”

“In addition to this, we have maintained a consistent track record of paying regular dividends to promote a stable stream of return to our loyal shareholders,” he added.

“As we look towards financial year 2013, we intend to nurture the immense potential inherent within the Group. With a pipeline of products that we hope to introduce in stages, along with sales opportunities in the private and public sector, we are confident of our prospects barring unforeseen circumstances,” he concluded.

Forward looking statements

This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

-ends-

Issued on behalf of: **Pharmaniaga Berhad** By: **acorn communications sdn bhd**
For further information, please contact **Roshen Dev** at **016 251 8694** or **Syazwanee Ghazali** at **03 7958 8348**
Or send an e-mail to acorncommunications@acornco.com.my